60 Degrees Pharmaceuticals

SXTP on Nasdaq. Market value $2m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 8 funds in all.

Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

7 investors own more than 5%.

  • Knight Therapeutics Inc.
    Passive investor
    19.9%+19.9 pts
    Since 22 July 2026
  • Mitchell P. Kopin
    Passive investor
    at least 10.0%+0.9 pts
    (filed with 2 related holders)
    Since 30 September 2026
  • Orca Capital AG
    Passive investor
    5.6%+0.7 pts
    Since 5 November 2026
  • Lind Global Fund III LP
    Passive investor
    at least 5.5%
    (filed with 2 related holders)
    Since 31 July 2026
  • CVI Investments, Inc.
    Passive investor
    at least 5.3%−1.7 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • Armistice Capital, LLC
    Passive investor
    at least 5.0%−5.0 pts
    (filed with 1 related holder)
    Since 31 March 2025
  • Ayrton Capital LLC
    Passive investor
    at least 4.1%−5.8 pts
    (filed with 2 related holders)
    Since 30 September 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $30,085 of shares on the open market.

  • DOW GEOFFREY S
    President and CEO, Director
    Bought
    Date
    12 June 2026
    Shares
    7,350
    Price
    $1.38
    Value
    $10,143
  • DOW GEOFFREY S
    President and CEO, Director
    Bought
    Date
    15 December 2025
    Shares
    9,670
    Price
    $0.80
    Value
    $7,736
  • DOW GEOFFREY S
    President and CEO, Director
    Bought
    Date
    11 December 2025
    Shares
    3,613
    Price
    $0.92
    Value
    $3,324
  • DOW GEOFFREY S
    President and CEO, Director
    Bought
    Date
    10 December 2025
    Shares
    9,350
    Price
    $0.95
    Value
    $8,883

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

2 serious warning signs in 60 Degrees Pharmaceuticals’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 13 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.”
    Show the full paragraph
    Continuation as a going concern is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from the Company’s single marketed product. To achieve profitability, the Company expects it will need to raise additional capital to fund its activities relating to commercial support for its existing product and any future clinical research trials and operating activities. However, there can be no assurance that it will ever achieve or maintain profitability. Accordingly, there is no assurance that the Company will be able to obtain the additional capital necessary to fund its operations during the look ‑ forward period. These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.

    From the 10-Q filed 16 November 2026, Part I, Item 1. Financial Statements. Read it in the filing

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based on that evaluation, our Chief Executive Officer and the Company’s Chief Financial Officer have concluded that as of September 30, 2026 , due to the existence of the material weakness in our internal control over financial reporting described below, our disclosure controls and procedures were not effective.”
    Show the full paragraph
    Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026 . Based on that evaluation, our Chief Executive Officer and the Company’s Chief Financial Officer have concluded that as of September 30, 2026 , due to the existence of the material weakness in our internal control over financial reporting described below, our disclosure controls and procedures were not effective.

    From the 10-Q filed 16 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

  • One big customer

    Worth knowing

    One customer brings in a big share of sales: 92% last year. Losing that customer would hurt.

    “For the year ended December 31, 2025, our U.S. pharmaceutical distributor accounted for 92% of our total net product sales and Kodatef sales to our Australian distributor accounted for 6% of total net product sales (95% and 5% for the year ended December 31, 2024, respectively).”

    From the 10-K filed 30 March 2026, Item 7. Management's Discussion and Analysis. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.